Literature DB >> 9261380

Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism.

P Spearman1, R Horton, L Ratner, I Kuli-Zade.   

Abstract

The interaction of the human immunodeficiency virus (HIV) Gag protein with the plasma membrane of a cell is a critical event in the assembly of HIV particles. The matrix protein region (MA) of HIV type 1 (HIV-1) Pr55Gag has previously been demonstrated to confer membrane-binding properties on the precursor polyprotein. Both the myristic acid moiety and additional determinants within MA are essential for plasma membrane binding and subsequent particle formation. In this study, we demonstrated the myristylation-dependent membrane interaction of MA in an in vivo membrane-binding assay. When expressed within mammalian cells, MA was found both in association with cellular membranes and in a membrane-free form. In contrast, the intact precursor Pr55Gag molecule analyzed in an identical manner was found almost exclusively bound to membranes. Both membrane-bound and membrane-free forms of MA were myristylated and phosphorylated. Differential membrane binding was not due to the formation of multimers, as dimeric and trimeric forms of MA were also found in both membrane-bound and membrane-free fractions. To define the requirements for membrane binding of MA, we analyzed the membrane binding of a series of MA deletion mutants. Surprisingly, deletions within alpha-helical regions forming the globular head of MA led to a dramatic increase in overall membrane binding. The stability of the MA-membrane interaction was not affected by these deletions, and no deletion eliminated membrane binding of the molecule. These results establish that myristic acid is a primary determinant of the stability of the Gag protein-membrane interaction and provide support for the hypothesis that a significant proportion of HIV-1 MA molecules may adopt a conformation in which myristic acid is hidden and unavailable for membrane interaction.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261380      PMCID: PMC191936     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Product review. New mammalian expression vectors.

Authors:  B Moss; O Elroy-Stein; T Mizukami; W A Alexander; T R Fuerst
Journal:  Nature       Date:  1990-11-01       Impact factor: 49.962

2.  Differential membrane binding of the human immunodeficiency virus type 1 matrix protein.

Authors:  W Zhou; M D Resh
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

3.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

4.  Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.

Authors:  H G Göttlinger; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

5.  Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.

Authors:  M Bryant; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

6.  HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase.

Authors:  P Gallay; S Swingler; J Song; F Bushman; D Trono
Journal:  Cell       Date:  1995-11-17       Impact factor: 41.582

7.  Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.

Authors:  A Carrillo; L Ratner
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

8.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

Authors:  V Karacostas; K Nagashima; M A Gonda; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA.

Authors:  A G Bukrinskaya; A Ghorpade; N K Heinzinger; T E Smithgall; R E Lewis; M Stevenson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import.

Authors:  P Gallay; V Stitt; C Mundy; M Oettinger; D Trono
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more
  130 in total

1.  Binding of human immunodeficiency virus type 1 Gag to membrane: role of the matrix amino terminus.

Authors:  A Ono; E O Freed
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

3.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein.

Authors:  Lisa Z Scheifele; Rachel A Garbitt; Jonathan D Rhoads; Leslie J Parent
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

5.  Localization of human immunodeficiency virus type 1 Gag and Env at the plasma membrane by confocal imaging.

Authors:  L Hermida-Matsumoto; M D Resh
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera.

Authors:  J B Bowzard; R J Visalli; C B Wilson; J S Loomis; E M Callahan; R J Courtney; J W Wills
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Decoding the intrinsic mechanism that prohibits ALIX interaction with ESCRT and viral proteins.

Authors:  Xi Zhou; Jiali Si; Joe Corvera; Gary E Gallick; Jian Kuang
Journal:  Biochem J       Date:  2010-12-15       Impact factor: 3.857

8.  The late stage of human immunodeficiency virus type 1 assembly is an energy-dependent process.

Authors:  M Tritel; M D Resh
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

9.  Entropic switch regulates myristate exposure in the HIV-1 matrix protein.

Authors:  Chun Tang; Erin Loeliger; Paz Luncsford; Isaac Kinde; Dorothy Beckett; Michael F Summers
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-29       Impact factor: 11.205

10.  Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.

Authors:  Tatyana Dorfman; Elena Popova; Massimo Pizzato; Heinrich G Göttlinger
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.